A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
Recruiting now Phase 2 NCT07470879
Run by Pfizer · for 2 to 11 · All sexes
What this study is about
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics participants (≥ 2 years up to \< 12 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).
Who can join (things the study team will check)
Inclusion criteria: Have a diagnosis of ulcerative colitis (UC) that is moderately to severely active Participants are permitted to be receiving a therapeutic dose of select UC therapies Exclusion criteria: Severe extensive colitis Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis…
Where this trial is running
- Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada
- Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada
- CHU de Québec - Université Laval, Québec, Quebec, Canada
- Hospices Civils de Lyon - Hôpital Femme Mère Enfant, Bron, Auvergne-Rhône-Alpes, France
- Hôpital Universitaire Necker Enfants Malades, Paris, France
- Universitätsklinikum Münster - Albert Schweitzer Campus, Münster, North Rhine-Westphalia, Germany
- Universitätsklinikum Leipzig, Leipzig, Saxony, Germany
- Universitaetsklinikum Tuebingen, Tübingen, Germany
- HELIOS Klinikum Wuppertal, Wuppertal, Germany
- Sheba Medical Center, Ramat Gan, Central District, Israel
- Yitzhak Shamir Medical Center, Ẕerifin, Central District, Israel
- Shaare Zedek Medical Center, Jerusalem, Jerusalem, Israel
+ 13 more sites.
Who to contact
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07470879.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.